# Claude Opus 4.6 / inf-d01

Original final answer, shared by both scoring rounds.

# Analysis Design: Identifying a Reproducible Treatment-Associated Multi-Omic Program from Paired Tumor Samples

---

## 1. SUMMARY CONCLUSION AND RECOMMENDED ACTION

The goal is to extract a single, coherent treatment-associated molecular program from three data layers (RNA, protein, metabolite) measured in paired pre-/post-treatment tumor biopsies from 30 patients. The critical threats are (i) batch–condition confounding in metabolomics (M2), (ii) incomplete observations (M3), and (iii) overfitting a program that cannot replicate. The recommended strategy is: rigorously correct or flag batch effects first, then perform within-patient differential analysis independently per omic, integrate the three layers through convergent enrichment onto shared biological processes, define the program as a consensus process-level signature, and finally lock-validate it in the untouched second cohort (M4). Integration provides biological coherence across noisy individual layers; enrichment maps molecular-level changes to interpretable processes and absorbs platform-specific noise; external validation tests whether the program generalises beyond the discovery set and its technical artefacts.

---

## 2. SCIENTIFIC ARGUMENT AND EVIDENCE-TO-INFERENCE CHAIN

### 2.1 Rationale for a Paired, Multi-Omic, Process-Level Approach

**Evidence → Inference → Conclusion chain:**

- *Evidence (M1):* Each patient provides a pre- and post-treatment sample, giving 30 biological pairs.
- *Inference:* A paired design controls inter-patient heterogeneity and increases power for detecting treatment effects relative to an unpaired comparison of equivalent total sample size.
- *Conclusion:* Use each patient as their own control; the estimand is the within-patient change attributable to treatment.

- *Evidence (M2, M3):* Platforms differ in batch structure and completeness.
- *Inference:* Any single platform may carry platform-specific artefacts or gaps; requiring convergence across platforms filters these out.
- *Conclusion:* Analyse each omic independently first (to avoid propagating one layer's artefacts into another), then integrate at the pathway/process level where the three layers can legitimately intersect.

- *Evidence (M4):* A second cohort exists but must remain untouched.
- *Inference:* All model selection, threshold tuning, and program definition must be completed before the validation cohort is opened.
- *Conclusion:* Strict temporal separation: lock the program definition, pre-register the validation test statistic and acceptance threshold, then apply once.

### 2.2 Roles of Integration, Enrichment and External Validation

| Component | Role | Why it is necessary |
|---|---|---|
| **Integration** | Combines evidence from RNA, protein and metabolite changes into a single program | Any one layer is noisy and incomplete (M3); convergent signals across biochemically linked layers are less likely to be artefactual |
| **Enrichment** | Maps lists of individually significant molecules to curated biological processes (gene-set, pathway, metabolite-set) | Reduces dimensionality, absorbs measurement-level noise, provides interpretable biology, and creates a common ontological space where RNA/protein and metabolites can be compared |
| **External validation** | Tests the locked program in an independent cohort (M4) | Guards against overfitting to discovery-set batch structure, patient composition, or analytic degrees of freedom; provides an unbiased estimate of program reproducibility |

---

## 3. OPERATIONAL PROTOCOL (Ordered)

### Phase A — Preparation and Quality Checks

**A1. Data inventory and missingness characterisation**

1. Catalogue every sample × assay combination; encode presence/absence in a 60 × 3 matrix (30 patients × 2 time-points; 3 omic layers).
2. Classify missingness mechanism: missing-completely-at-random (MCAR, testable via Little's test within each omic) vs. missing-not-at-random (e.g., low-abundance metabolites below LOD). This determines imputation eligibility (see A4).
3. *Acceptance criterion (A1):* Proceed only if ≥ 20 patients have complete pairs for at least two of three omic layers. If fewer, power is insufficient and the study should be redesigned.

**A2. Batch-effect audit**

- For RNA and protein: record batch labels per sample. Use principal-component analysis (PCA) and association tests (ANOVA of PC1–5 versus batch and versus condition [pre/post]) to quantify batch variance.
- For metabolomics: because most post-treatment samples share a batch (M2), batch and condition are heavily confounded. Quantify the degree of confounding by computing the Cramér's V between batch and condition labels.
  - *If V > 0.8 (near-total confounding):* metabolomics differential results cannot be separated from batch effects by standard linear correction. Flag metabolomics as supportive-only (can confirm RNA/protein findings but cannot independently nominate features).
  - *If V < 0.8:* a subset of post-treatment samples exists in other batches; these can anchor a correction model. Use ComBat or similar empirical-Bayes batch correction protecting the condition variable.
- For RNA/protein where batch and condition are not confounded: apply ComBat (or limma's removeBatchEffect for visualisation) with condition as a protected covariate.

**A3. Within-platform normalisation**

- RNA: library-size normalisation (e.g., TMM or median-of-ratios), then variance-stabilising transformation.
- Protein: median-centering per run, log2 transformation, and (if applicable) bridge-sample alignment across batches.
- Metabolites: total-ion-current normalisation, log transformation, quality-control sample–based drift correction if QC injections are available.

**A4. Imputation (where justified)**

- For features missing in < 30 % of samples and plausibly MCAR: k-nearest-neighbour imputation within each omic separately.
- For features systematically absent in one condition: treat as informatively missing; model with left-censored methods or analyse only the observed subset.
- *Record:* identity and fraction of imputed values per feature for sensitivity analysis later.

**A5. Outlier and sample-quality filters**

- Remove samples that are clear outliers on PCA (> 3 SD on PC1 or PC2), verifying the cause (degradation, mislabel).
- Verify paired-sample identity: for RNA data, use SNP-level concordance from RNA-seq genotypes (or analogous protein/metabolite identity markers). Mislabelled pairs must be excluded.

---

### Phase B — Independent Per-Omic Differential Analysis (Discovery)

Each omic is analysed separately to avoid cross-contamination of artefacts.

**B1. Define the statistical model**

For each omic, fit a paired model:

    Y_ij = μ + Patient_i + Condition_j + ε_ij

- RNA: use limma-voom or DESeq2 with a patient-blocking factor. Obtain per-gene log2 fold-change (post vs. pre) and moderated t-statistics.
- Protein: analogous linear mixed model (patient as random effect) or paired moderated t-test via limma.
- Metabolites: paired Wilcoxon or paired linear model per feature, depending on distributional behaviour.

**B2. Multiple-testing correction**

- Apply Benjamini–Hochberg FDR per omic. Use FDR < 0.05 as the threshold for a "significant" feature list.
- Also retain the full ranked list (by signed –log10 p or t-statistic) for ranked enrichment methods.

**B3. Sensitivity analyses**

- Re-run excluding imputed values; check concordance of top hits.
- For metabolomics (if batch is confounded, per A2): compare results obtained from the corrected full dataset with results from the unconfounded subset of samples only. If top features disagree, downweight metabolomics-only findings.

---

### Phase C — Enrichment Analysis (Mapping to Processes)

**C1. Gene/protein enrichment**

- Use Gene Set Enrichment Analysis (GSEA) or fast pre-ranked alternatives (fgsea) on the signed, ranked gene/protein lists against curated pathway databases (Reactome, KEGG, Hallmark gene sets).
- Report normalised enrichment scores (NES) and FDR q-values.

**C2. Metabolite-set enrichment**

- Map identified metabolites to KEGG compound IDs; run metabolite-set enrichment analysis (MSEA) via MetaboAnalyst's SMPDB or KEGG metabolic pathway sets using the ranked metabolite list.
- Report equivalent enrichment statistics.

**C3. Cross-omic process convergence**

- Identify biological processes (pathways) that are significantly enriched (FDR < 0.1) in at least two of the three omic layers (RNA, protein, metabolite).
- This is the operational definition of a "treatment-associated program": a set of convergent processes supported by independent molecular evidence.
- Quantify convergence formally: for each pathway, combine per-omic p-values using Fisher's or Stouffer's method (weighting by effective sample size per omic). Correct the combined p-values for multiple pathways.

*Why enrichment-level integration rather than feature-level?*
Features across platforms do not share the same identifiers or scales (a gene is not a metabolite). Pathway databases provide the ontological bridge. Furthermore, enrichment absorbs individual feature noise and batch residuals, yielding more stable signals.

---

### Phase D — Program Definition and Internal Stability Assessment

**D1. Lock the program**

- The treatment-associated program = the set of convergent pathways from C3 plus their constituent leading-edge genes, proteins and metabolites.
- Derive a per-patient "program activity score": for each omic, compute a summary score per patient-pair (e.g., ssGSEA delta for RNA, analogous weighted mean for protein and metabolites). Average the standardised per-omic scores to get a single composite program-activity score per patient.

**D2. Internal stability (not validation)**

- Leave-one-patient-out (LOO) stability: re-run B–C omitting one patient at a time. Measure the Jaccard similarity of the pathway set selected each time. A stable program should have Jaccard > 0.7 across LOO iterations.
- Split-half reproducibility: randomly split the 30 patients into two halves (1,000 permutations); measure how often each pathway is selected in both halves. Pathways appearing in > 80 % of split-halves are "core."
- *Acceptance criterion (D2):* A core program of ≥ 3 convergent pathways with split-half reproducibility > 80 % must exist to proceed to validation. If not met, relax the per-omic FDR to 0.15, or accept two-omic convergence, re-assess, and document the relaxation.

**D3. Document all analytic decisions**

Before touching M4, write a locked analysis plan specifying:
- Exact pathway list constituting the program.
- Formula for computing program-activity score in new samples.
- Pre-registered test: "In the validation cohort, the paired program-activity score (post minus pre) will be significantly > 0 (one-sided paired t-test or Wilcoxon, α = 0.05)."

---

### Phase E — External Validation (M4 Cohort)

**E1. Process the validation cohort identically**

- Apply the same normalisation, batch-correction parameters (if applicable; re-estimate batch parameters within the new cohort, do not transfer discovery batch-correction coefficients), and feature-filtering steps.
- Compute per-patient program-activity scores using the locked gene/protein/metabolite lists and scoring formula.

**E2. Pre-registered hypothesis test**

- Perform the one-sided paired test specified in D3.
- *Acceptance criterion:* p < 0.05 and effect-size direction concordant with discovery.
- Report the effect size (Cohen's d for the paired difference) and its 95 % confidence interval.

**E3. Sensitivity and exploratory analyses (post-hoc)**

- If some omic layers are unavailable in the validation cohort, test each available single-omic component of the program separately.
- Examine whether program activity correlates with clinical response if response data are available (exploratory, not pre-registered, clearly labelled).

---

### Phase F — Controls, Blinding, and Allocation

| Element | Implementation |
|---|---|
| **Independent units** | The 30 patients (paired within); each patient contributes one paired observation. All statistical tests respect this (paired tests, patient as blocking factor). |
| **Allocation and blinding** | There is no randomisation of treatment (observational paired design). Analyst blinding: during batch-correction and QC (Phases A–B), condition labels should be masked where possible. In practice, the analyst must know labels for the batch audit; therefore a second analyst should independently replicate the enrichment and integration steps (C–D). |
| **Positive controls** | Include known treatment-mechanism pathways (if prior pharmacology suggests a target pathway, verify it appears at single-omic level as a sanity check). |
| **Negative controls** | Permutation null: permute pre/post labels within patients 1,000 times; repeat entire B–C pipeline. The number of convergent pathways under permutation gives an empirical null for the program size observed in real data. If the real program is not larger than the 95th percentile of the null, the signal is indistinguishable from noise. |
| **Technical controls** | Use replicate QC samples (if available) to estimate technical coefficient of variation per feature; exclude features with CV > 30 % in QCs. |

---

## 4. CALIBRATION PROCEDURES FOR UNKNOWN PARAMETERS

Several parameters are study-specific and cannot be set a priori:

| Parameter | Calibration procedure |
|---|---|
| FDR threshold per omic | Start at 0.05; if < 50 features pass in any omic, relax to 0.10 and document. |
| Minimum pathway size for enrichment | Run across 10–200 gene sets; inspect stability of top results. Standard default: 15–500 genes. |
| Number of convergent omics required | Default ≥ 2 of 3; if metabolomics is fully confounded (Phase A2), require RNA + protein convergence; metabolomics becomes confirmatory only. |
| Imputation fraction cap | Set empirically: test programme stability at 10 %, 20 %, 30 % caps; choose the cap beyond which the pathway list changes materially. |
| Composite score weighting | Default: equal weights. If one omic has substantially fewer patients (M3), weight by √(n_complete_pairs) for that omic. |

---

## 5. TROUBLESHOOTING AND STOPPING RULES

| Problem | Action |
|---|---|
| Metabolomics batch entirely confounded (V ≈ 1) | Exclude metabolomics from nomination; retain only for post-hoc confirmation of RNA+protein program. |
| Fewer than 20 complete pairs across any two omics | Insufficient power. Consider imputation or reducing the analysis to the two best-covered omics. |
| No pathway reaches convergence across two omics | Relax thresholds stepwise (FDR 0.10 → 0.15); if still empty, report null result — the treatment may not induce a coherent multi-omic program detectable at n = 30. |
| Internal stability (D2) fails | The program is unstable. Do not proceed to validation; instead report the individual omic results descriptively and recommend a larger discovery cohort. |
| Validation (E2) fails | The program does not replicate. Report discovery findings with the failed validation prominently. Investigate whether the validation cohort differs in clinical characteristics; generate hypotheses for a revised study. |

---

## 6. ALTERNATIVES AND LIMITS

**Alternative integration strategies considered:**

1. *Multi-omic factor methods (MOFA, DIABLO/sPLS):* These learn latent factors from all omics simultaneously. Advantage: data-driven, can discover novel cross-omic structure. Disadvantage: with n = 30 and batch confounding, these methods risk fitting technical variation; they also make the program harder to interpret biologically and harder to apply in the validation cohort, which may lack one omic layer. We therefore prefer the enrichment-convergence approach but note that MOFA could be run as a secondary exploratory analysis.

2. *Network-based integration (WGCNA + metabolite modules):* Identifies co-expression modules, then tests module–treatment association. Viable, but module detection is unstable at n = 30 and network methods require complete data.

3. *Simple overlap of significant features mapped to genes:* Loses metabolite information (metabolites map to pathways, not genes one-to-one) and is overly sensitive to arbitrary thresholds.

**Key limits of the design:**

- **n = 30 paired observations** provides moderate power for large paired effects (Cohen's d ≥ 0.6, power ≈ 0.80 at α = 0.05 for a paired t-test). Subtle programs will be missed.
- **Batch–condition confounding in metabolomics (M2)** is the single largest threat to validity. If not resolvable, metabolomics evidence must be downweighted.
- **Missing data (M3)** reduce effective sample size per omic unevenly, potentially biasing the enrichment towards the most complete platform.
- **Paired design assumes the biopsy site and tumour heterogeneity** do not systematically differ between time-points; spatial sampling bias could mimic a treatment effect.
- **The held-out cohort (M4) is described as "small"**, limiting the power of validation. A non-significant validation result could reflect low power rather than non-reproducibility; the validation effect-size estimate and its CI should be interpreted alongside the p-value.

---

## 7. SUMMARY: EVIDENCE-TO-CONCLUSION CHAIN

1. Paired samples (M1) → within-patient differential → controls inter-patient heterogeneity.
2. Batch structure (M2) → rigorous batch audit and conditional correction → prevents false treatment signals.
3. Missing data (M3) → characterisation, principled imputation, sensitivity analysis → maintains sample size while flagging fragile results.
4. Independent per-omic analysis → avoids artefact propagation → three clean ranked lists.
5. Enrichment onto shared pathways → common ontological space, noise absorption → interpretable process-level changes.
6. Cross-omic convergence (≥ 2 layers agree) → the "treatment-associated program" → high specificity for real biology.
7. Internal stability (LOO, split-half) → confirms the program is not driven by a few patients → readiness for validation.
8. Locked program + pre-registered test → applied once to the untouched cohort (M4) → unbiased reproducibility assessment.

Each step is traceable to the evidence constraints (M1–M4), and each analytic decision has a calibration procedure rather than an assumed value. The design prioritises guarding against the dominant risk — confusing batch effects or overfitting with treatment biology — while maximising the biological interpretability and external generalisability of the resulting program.
